[{"address1": "121 Richmond Street West", "address2": "Penthouse Suite, 1300", "city": "Toronto", "state": "ON", "zip": "M5H2K1", "country": "Canada", "phone": "416-346-7764", "website": "https://www.psyencebiomed.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Jody  Aufrichtig", "age": 49, "title": "Co-Founder, Executive Chairman & Strategic Business Development Officer", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 110302, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Neil  Maresky M.D.", "age": 58, "title": "CEO & Director", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 231228, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Warwick Ron Corden-Lloyd", "age": 43, "title": "Chief Financial Officer", "yearBorn": 1980, "fiscalYear": 2024, "totalPay": 98346, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Taryn  Vos", "title": "General Counsel", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Mary-Elizabeth  Gifford", "title": "Chief of Global Impact", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "maxAge": 86400, "priceHint": 4, "previousClose": 2.64, "open": 2.25, "dayLow": 2.1301, "dayHigh": 3.0, "regularMarketPreviousClose": 2.64, "regularMarketOpen": 2.25, "regularMarketDayLow": 2.1301, "regularMarketDayHigh": 3.0, "beta": -0.425, "volume": 1375157, "regularMarketVolume": 1375157, "averageVolume": 455805, "averageVolume10days": 2353409, "averageDailyVolume10Day": 2353409, "bid": 2.28, "ask": 2.49, "bidSize": 100, "askSize": 100, "marketCap": 2002792, "fiftyTwoWeekLow": 2.13, "fiftyTwoWeekHigh": 945.15, "fiftyDayAverage": 5.7473, "twoHundredDayAverage": 39.0347, "currency": "USD", "enterpriseValue": 10297195, "floatShares": 1865988, "sharesOutstanding": 845060, "sharesShort": 671846, "sharesShortPriorMonth": 215100, "sharesShortPreviousMonthDate": 1727654400, "dateShortInterest": 1730332800, "sharesPercentSharesOut": 0.0106, "heldPercentInsiders": 0.11137, "heldPercentInstitutions": 0.089770004, "shortRatio": 0.08, "shortPercentOfFloat": 0.0115, "impliedSharesOutstanding": 63379600, "bookValue": -0.819, "lastFiscalYearEnd": 1711843200, "nextFiscalYearEnd": 1743379200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -51159048, "trailingEps": -586.5, "lastSplitFactor": "1:75", "lastSplitDate": 1732579200, "enterpriseToEbitda": -3.742, "52WeekChange": -0.9971273, "SandP52WeekChange": 0.31754446, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "PBM", "underlyingSymbol": "PBM", "shortName": "Psyence Biomedical Ltd.", "longName": "Psyence Biomedical Ltd.", "firstTradeDateEpochUtc": 1639146600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "d1845321-382a-3311-8b82-3791bbf94fb2", "messageBoardId": "finmb_698500412", "gmtOffSetMilliseconds": -18000000, "currentPrice": 2.37, "recommendationKey": "none", "totalCash": 733188, "totalCashPerShare": 0.055, "ebitda": -2751584, "totalDebt": 10447889, "quickRatio": 0.064, "currentRatio": 0.093, "returnOnAssets": -1.2635, "freeCashflow": -1711982, "operatingCashflow": -2945367, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-12-07"}]